A case report published in BMC Infectious Diseases describes a middle-aged female with immune thrombocytopenia who developed refractory Campylobacter coli cellulitis accompanied by recurrent fever and severe hypogammaglobulinemia after undergoing chimeric antigen receptor T-cell therapy in a clinical trial.
Chimeric antigen receptor T-cell therapy has demonstrated efficacy in treating B-cell malignancies and autoimmune disorders, but on-target depletion of normal B cells through the targeting of CD19 or B-cell maturation antigen frequently produces secondary hypogammaglobulinemia. This targeted depletion substantially elevates the risk of opportunistic complications, though Campylobacter coli bloodstream infection presenting as persistent cellulitis has rarely been documented in this clinical setting.
Following chimeric antigen receptor T-cell infusion, the patient achieved complete remission of immune thrombocytopenia, maintaining a platelet count of 362 × 10⁹/L during the documented hospitalization. However, two months after the infusion, she presented with persistent bilateral lower limb cellulitis and recurrent fever that failed to respond over more than two months to multiple broad-spectrum antibiotic regimens, including levofloxacin, cefoperazone-sulbactam, and clindamycin.
An immunological evaluation revealed profound B-cell aplasia with 0 percent CD19-positive cells alongside severe pan-hypogammaglobulinemia, characterized by an immunoglobulin G level of 1.4 g/L, an immunoglobulin A level below 0.07 g/L, and an immunoglobulin M level below 0.004 g/L. Subsequent blood cultures identified the underlying pathogen as Campylobacter coli, an atypical bacterial agent that serves as an exceptionally rare cause of skin and soft tissue infection.
Resolution of the refractory infection was achieved through targeted administration of meropenem combined with intravenous immunoglobulin replacement therapy. During follow-up examinations, the patient exhibited complete clinical resolution, with total clearing of the bilateral lower extremity skin lesions and no recurrence of fever.
The reporting authors concluded that the case highlights the vulnerability of chimeric antigen receptor T-cell recipients with severe hypogammaglobulinemia to atypical extraintestinal Campylobacter infections. Based on these observations, they emphasized the necessity of prompt pathogen-directed diagnostics, dual antimicrobial and immunoglobulin replacement strategies, and the potential integration of routine immunoglobulin monitoring and intravenous immunoglobulin protocols into long-term post-therapy management.
Subject of Research: Refractory Campylobacter coli cellulitis and severe hypogammaglobulinemia following CAR-T cell therapy for immune thrombocytopenia
Article Title: Refractory Campylobacter coli cellulitis in severe hypogammaglobulinemia after CAR-T cell therapy for immune thrombocytopenia: a case report
Article References: Xiao, X., Zheng, X.-L., Cheng, Z., Zhou, H.-L., Huang, S.-W., & Hu, Q. (2026). Refractory Campylobacter coli cellulitis in severe hypogammaglobulinemia after CAR-T cell therapy for immune thrombocytopenia: a case report. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14371-7
Image Credits: AI Generated
DOI: 10.1186/s12879-026-14371-7
Keywords: Campylobacter coli, cellulitis, CAR-T cell therapy, severe hypogammaglobulinemia, immune thrombocytopenia, B-cell aplasia, pan-hypogammaglobulinemia, intravenous immunoglobulin, meropenem, opportunistic infections, bloodstream infection, CD19, B-cell maturation antigen, levofloxacin, cefoperazone-sulbactam, clindamycin, platelet count, recurrent fever
News Source: Kristina Jarvis. (November 11, 2026). CAR-T Cell Therapy Recipient Develops Rare Refractory Campylobacter Coli Infection. Scienmag.



